Healogix

Our Technology

Back to About Healogix

Our proprietary ASEMAP-H® technology is the next generation of conjoint analytics.

ASEMAP-H helps identify and prioritize the bases of prescriber, patient and/or payer choice/value drivers from a larger number of attributes (up to 60 attributes, across up to 11 levels each) than any other methodology.

• The Adaptive Self-Explicated method (ASE) offers a simpler, web-based approach for multi-attribute preference measurement
• By using the power of interactive computer-driven data collection, ASE allows for constant sum measurement of a large number of attribute importance comparisons in a relatively short interview
• The ASE method produces greater variability in attribute importance relative to the other “leading edge” analytic methodologies (such as Adaptive Conjoint Analysis and Fast Polyhedral Analysis)
• The ASE method provides a substantially higher predictive validity compared to those methods, as well as compared to traditional Self-Explication

ASEMAP-H is proven to have greater predictive and discriminating power than any other methodology for large numbers of attributes − but the best news is that it does NOT require any larger sample size than currently prevalent methods.

While traditional methods have focused on efficacy/safety/tolerability endpoints, the growing influence of patient-payers can only be accommodated by looking at treatment benefits from the standpoint of all the stakeholders. The result is a comprehensive and clear understanding of how prescribers, patients and/or payers view the ability of a new drug therapy to address their concerns relative to prospective usage and to predict the thresholds at which they would change their behaviors. From this we can generate valid projections of share preference and, ultimately, commercial success over time.